×
About 31,916 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  15,495 results

Reduced Occipital Cortex Excitability in Amyotrophic Lateral Sclerosis.
https://doi.org/10.1097/WNP.0000000000000805
Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society; Cengiz B, Fidancı H et. al.

Jan 14th, 2021 - In addition to motor cortex involvement, sensory abnormalities have been demonstrated in amyotrophic lateral sclerosis (ALS), including structural and metabolic alterations in the occipital cortex. The aim of this study was to examine occipital ex...

Problem-focused coping underlying lower caregiver burden in ALS-FTD: implications for c...
https://doi.org/10.1080/21678421.2020.1867180
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Caga J, Zoing MC et. al.

Jan 13th, 2021 - Objective: Amyotrophic lateral sclerosis (ALS) is a multisystem neurodegenerative disorder which includes cognitive and behavioral symptoms akin to frontotemporal dementia (FTD). Despite the necessity of caregiver intervention to assist with the m...

Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic latera...
https://doi.org/10.1093/brain/awaa340
Brain : a Journal of Neurology; Sassani M, Alix JJ et. al.

Jan 13th, 2021 - Mitochondrial dysfunction is postulated to be central to amyotrophic lateral sclerosis (ALS) pathophysiology. Evidence comes primarily from disease models and conclusive data to support bioenergetic dysfunction in vivo in patients is currently lac...

Inducible expression of human C9ORF72 36x G4C2 hexanucleotide repeats is sufficient to ...
https://doi.org/10.1242/dmm.044842
Disease Models & Mechanisms; Riemslagh FW, van der Toorn EC et. al.

Jan 12th, 2021 - The hexanucleotide G4C2 repeat expansion in the first intron of the C9ORF72 gene explains the majority of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) cases. Numerous studies have indicated the toxicity of dipeptide repeat...

Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled s...
https://doi.org/10.1136/bmjopen-2020-041479
BMJ Open; Vucic S, Kiernan MC et. al.

Jan 12th, 2021 - Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive and universally fatal neurodegenerative disorder. In Europe, Australia and Canada, riluzole is the only approved therapeutic agent for the treatment of ALS, while in the USA, riluz...

see more →

Guidelines  9 results

Aquestive Therapeutics Receives FDA Approval for Exservan (riluzole) Oral Film
http://aquestive.com/aquestive-therapeutics-receives-fda-approval-for-exservan-riluzole-oral-film/

Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-act...

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 8th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

MDA U.S. Neuromuscular Disease Registry
https://www.mda.org/services/neuromuscular-disease-registry
Muscular Dystrophy Association (USA)

Dec 31st, 2015 - In 2013, MDA launched the U. S.

EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--rev...
https://doi.org/10.1111/j.1468-1331.2011.03501.x
European Journal of Neurology; , Andersen PM et. al.

Sep 14th, 2011 - The evidence base for the diagnosis and management of amyotrophic lateral sclerosis (ALS) is weak. To provide evidence-based or expert recommendations for the diagnosis and management of ALS based on a literature search and the consensus of an exp...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 13th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  31 results see all →

Clinicaltrials.gov  15,905 results

Reduced Occipital Cortex Excitability in Amyotrophic Lateral Sclerosis.
https://doi.org/10.1097/WNP.0000000000000805
Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society; Cengiz B, Fidancı H et. al.

Jan 14th, 2021 - In addition to motor cortex involvement, sensory abnormalities have been demonstrated in amyotrophic lateral sclerosis (ALS), including structural and metabolic alterations in the occipital cortex. The aim of this study was to examine occipital ex...

Problem-focused coping underlying lower caregiver burden in ALS-FTD: implications for c...
https://doi.org/10.1080/21678421.2020.1867180
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Caga J, Zoing MC et. al.

Jan 13th, 2021 - Objective: Amyotrophic lateral sclerosis (ALS) is a multisystem neurodegenerative disorder which includes cognitive and behavioral symptoms akin to frontotemporal dementia (FTD). Despite the necessity of caregiver intervention to assist with the m...

Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic latera...
https://doi.org/10.1093/brain/awaa340
Brain : a Journal of Neurology; Sassani M, Alix JJ et. al.

Jan 13th, 2021 - Mitochondrial dysfunction is postulated to be central to amyotrophic lateral sclerosis (ALS) pathophysiology. Evidence comes primarily from disease models and conclusive data to support bioenergetic dysfunction in vivo in patients is currently lac...

Inducible expression of human C9ORF72 36x G4C2 hexanucleotide repeats is sufficient to ...
https://doi.org/10.1242/dmm.044842
Disease Models & Mechanisms; Riemslagh FW, van der Toorn EC et. al.

Jan 12th, 2021 - The hexanucleotide G4C2 repeat expansion in the first intron of the C9ORF72 gene explains the majority of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) cases. Numerous studies have indicated the toxicity of dipeptide repeat...

Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled s...
https://doi.org/10.1136/bmjopen-2020-041479
BMJ Open; Vucic S, Kiernan MC et. al.

Jan 12th, 2021 - Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive and universally fatal neurodegenerative disorder. In Europe, Australia and Canada, riluzole is the only approved therapeutic agent for the treatment of ALS, while in the USA, riluz...

see more →

News  449 results

VA Study Finds More ALS Hospitalizations With Edaravone
https://www.staging.medscape.com/viewarticle/938926

Oct 14th, 2020 - NEW YORK (Reuters Health) - Amyotrophic lateral sclerosis (ALS) patients prescribed edaravone are hospitalized more frequently, a new surveillance study in U.S. military veterans shows. Patients on edaravone had significantly higher rates of all-c...

VA Study Finds More ALS Hospitalizations With Edaravone
https://www.medscape.com/viewarticle/938926

Oct 14th, 2020 - NEW YORK (Reuters Health) - Amyotrophic lateral sclerosis (ALS) patients prescribed edaravone are hospitalized more frequently, a new surveillance study in U.S. military veterans shows. Patients on edaravone had significantly higher rates of all-c...

Drug Combo Slows Functional Decline in ALS
https://www.staging.medscape.com/viewarticle/936885

Sep 2nd, 2020 - Treatment with a fixed-dose combination of sodium phenylbutyrate and taurursodiol (AMX0035, Amylyx Pharmaceuticals) slows the rate of decline in physical function in patients with amyotrophic lateral sclerosis (ALS), according to results of the ph...

Drug Combo Slows Functional Decline in ALS
https://www.medscape.com/viewarticle/936885

Sep 2nd, 2020 - Treatment with a fixed-dose combination of sodium phenylbutyrate and taurursodiol (AMX0035, Amylyx Pharmaceuticals) slows the rate of decline in physical function in patients with amyotrophic lateral sclerosis (ALS), according to results of the ph...

New Hope for ALS
https://www.medscape.com/viewarticle/933672

Jul 8th, 2020 - Two early studies are raising hopes that some genetic forms of amyotrophic lateral sclerosis (ALS) can be treated. Both studies investigated potential benefits of suppressing the toxic activity in cells of a mutant gene (SOD1) that encodes superox...

see more →

Patient Education  27 results see all →